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Resumo:
Introdução: A pericardite aguda é uma síndrome frequente 
caracterizada pela inflamação do pericárdio e usualmente 
atribuído a etiologia viral/idiopática. Apesar dos avanços no 
tratamento, existe informação limitada em relação a etiologia e 
prognóstico. O objetivo do nosso trabalho foi identificar a pre-
valência de pericardite aguda com etiologia especifica e avaliar 
marcadores clínicos de prognóstico. 
Material e Métodos: Estudo retrospetivo de doentes hos-
pitalizados por pericardite aguda entre 2012-2016. A popula-
ção foi caracterizada quanto a etiologia, apresentação clínica, 
tratamento e prognóstico. Para avaliação de prognóstico 
foram avaliadas recorrência de pericardite, pericardite constri-
tiva e mortalidade global um ano após alta hospitalar. 
Resultados: Foram incluídos 94 doentes com idade me-
diana 46 anos (IIQ 32-61), 65% eram do sexo masculino. A 
etiologia idiopática foi responsável por 68% dos casos. Etio-
logia especifica foi identificada em 32% dos doentes, sendo 
mais frequente doença autoimune (12%) e neoplasia (5%). A 
pericardite idiopática foi mais associada a miopericardite (p 
= 0,049), enquanto a etiologia específica se associou a der-
rame pericárdico (p = 0,001) e a tamponamento pericárdico 
(p = 0,027). A recorrência de pericardite ocorreu em 13% dos 
doentes. O tratamento com corticosteroides em doentes com 
etiologia definida não se associou com aumento de recor-
rência (p = 0,220). A mortalidade global a um ano foi de 9%. 
A etiologia definida de pericardite aguda revelou-se o único 
preditor independente de mortalidade na análise multivariada 
(OR 40,3; 95% CI 1,9 – 137,2; p = 0,016). 
Conclusão: Cerca de um terço dos doentes hospitalizados 
por pericardite aguda têm uma causa específica identificável 
de pericardite e estes doentes apresentam risco aumentado 
de mortalidade.
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Abstract:
Introduction: Acute pericarditis is a common inflammatory 
condition of the pericardium usually assumed to be viral or id-
iopathic. Despite recent treatment improvements, information 
is scarce regarding etiology and prognosis. Our aim was to 
determine the incidence of pericarditis with a known etiology 
and assess clinical prognostic predictors. 
Material and Methods: A clinical retrospective analysis of 
hospitalized patients with acute pericarditis was conducted 
from 2012 to 2016. Population was characterized accord-
ing to etiology, clinical presentation, treatment and prognosis. 
Outcomes of interest, evaluated at one year after hospital dis-
charge, were pericarditis recurrence, hospitalization, constric-
tion and overall mortality. 
Results: A total of 94 patients were enrolled, median age 
46 years (inter-quartile range 32-61), 65% were male. Idio-
pathic etiology was responsible for 68% of cases. A specific 
etiology was found in the remaining 32% of patients, being 
the most frequent autoimmune disease (12%) and malignancy 
(5%). Idiopathic pericarditis was associated with myopericar-
ditis (p = 0.049) and a known etiology with pericardial effusion 
(p = 0.001) and cardiac tamponade (p = 0.027). Recurrence of 
pericarditis was found in 13% of patients. Corticosteroid treat-
ment in patients with an identified etiology was not associated 
with an increase in recurrence (p = 0.220). Overall 1-year mor-
tality was 9%. A defined etiology was the only independent 
predictor of mortality at multivariate analysis (OR 40.3; 95% CI 
1.9 – 137.2; p = 0.016). 
Conclusion: Up to one third of hospitalized patients with 
acute pericarditis have an identified cause of pericarditis and 
these patients are at increased risk of mortality.
Keywords: Acute Disease; Pericarditis/diagnosis; Pericar-
ditis/etiology; Pericarditis/therapy; Prognosis.
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Introduction
Acute pericarditis is the most common disease of the peri-
cardium. Its incidence is estimated in 27 cases per 100 000 
population per year in an urban European population1 and it is 
responsible for 0.1% of all hospital admissions.2 It affects mainly 
male patients aged between 16 and 65 years old.3 Although the 
clinical diagnosis of acute pericarditis may be relatively simple, 
the etiologic diagnosis is broad and varies according to multiple 
factors.3 Whereas in Sub-Saharan African countries tuberculo-
sis is the most important cause of acute pericarditis, in devel-
oped countries most cases have been classified as presumably 
viral or idiopathic.4-8 However, in some cases, pericarditis may 
reflect an underlying systemic disease.4,8
The treatment of acute pericarditis is based on the use 
of non-steroid anti-inflammatory drugs (NSAIDs), colchicine 
and the treatment of the underlying cause.9-11 The rate of re-
currence of pericarditis ranges from 15% - 40%.9 The over-
all prognosis is generally good, however few data concerning 
mortality and predictors of recurrence is available.3,8 The aim 
of our study was to assess the incidence of acute pericarditis 
with a known cause and to determine clinical parameters re-
lated to prognosis.
Material and Methods
A clinical retrospective observational study of patients 
identified between 2012 and 2016 in our Hospital was per-
formed. All patients aged 18 years or older hospitalized with 
a clinical diagnosis of acute pericarditis according to available 
criteria were included.3,4,7 Accepted criteria were at least two 
of the following: typical chest pain, pericardial friction rubs, 
recent widespread ST segment elevation or PR depressions 
and new pericardial effusion. Patients not fulfilling diagnostic 
criteria for acute pericarditis and those with missing data con-
cerning the etiology were excluded.
Data was analysed regarding demography, clinical pre-
sentation, etiology, treatment and prognosis. Clinical variables 
considered were the presence of myopericarditis, pericardial 
effusion and pericardial tamponade. A diagnosis of myoperi-
carditis was considered whenever a patient with the clinical 
diagnosis of acute pericarditis had evidence of elevated tro-
ponin I.12 Presence of pericardial effusion was assessed by 
transthoracic echocardiography. Cardiac tamponade was 
clinically established on patients with clinical signs of elevated 
jugular pressure or pulsus paradoxus, hemodynamic instabil-
ity (tachycardia or arterial hypotension) and echocardiographic 
evidence of large pericardial effusion (pericardial effusion of 
>20 mm with partial or total collapse of right heart chambers), 
without other cardiac diseases.12,13
Information considering etiology was derived from pa-
tients’ clinical records. There was no specific diagnostic pro-
tocol applied to all patients, so workup was individualized. 
Diagnostic strategy for viral etiology was not generally used 
as the list of probable virus is broad, serologic testing is not 
adequate and molecular diagnosis is expensive and time-con-
suming.12 For the purpose of this study, all patients with viral 
etiology or patients with no confirmed etiology, presumably 
viral, were classified as having idiopathic pericarditis. Blood 
tests included C-reactive protein (CRP), erythrocyte-sedimen-
tation rate (ESR) and high-sensitive troponin I. Data regarding 
treatment included therapy performed during hospitalization 
and after discharge. Prognosis was evaluated at one year after 
hospital discharge; we looked at pericarditis recurrence, hos-
pitalization for recurrence, constriction and overall mortality.
Analysis was performed using STATA MP version 14 (Stata-
Corp LLC®, Texas, USA). Categorical data was presented as 
counts and percentages and was analysed with chi-square 
test or the Fisher’s exact test, when the expected numbers are 
small (<5). Normality was tested with Kolmogorov-Smirnov 
test, showing that all continuous variables were skewed. The 
skewed distributions were described with medians and inter-
quartile ranges (IQR) and were compared with the use of the 
Mann-Whitney. These tests were performed to compare clini-
cal and laboratory features between patients with idiopathic 
pericarditis and those with defined etiology. In order to as-
sess predictors of mortality, clinical, laboratory and treatment 
variables were selected for a logistic regression analysis, as-
sessed by the estimated odds ratio (OR) with 95% confidence 
interval (CI). Firth logistic regression was applied whenever 
appropriate. Variables yielding p values of less than or equal 
to 0.10 in the bivariate analyses were entered into a multiple 
logistic regression model in which 1-year overall mortality was 
the outcome of interest. Two episodes of hospitalization for 
acute pericarditis from the same patient were treated as in-
dependent cases. The two-sided alpha level was set at 0.05.
Results
The population studied consisted of 94 patients with a 
median age of 46 years (32-61), 65% were male. Of all pa-
tients included, 57% had pericardial effusion, 34% had myo-
pericarditis and 10% had cardiac tamponade (Table 1). Only 
one patient with myopericarditis had left ventricular systolic 
dysfunction on echocardiogram that completely resolved 
during follow-up. In our cohort, 68% of cases were idiopath-
ic and 32% had an identified etiology. From these, the most 
frequent were autoimmune disease (12%), malignancy (5%) 
and post-myocardial injury syndrome (4%). Systemic lupus 
erythematosus was the most frequent autoimmune disease 
(6/11 patients), whereas lung cancer was the most frequent 
neoplasm (3/5 patients). In patients with autoimmune dis-
ease and malignancy, pericarditis was the first manifesta-
tion of disease in 18% and 80%, respectively. Six cases of 
pericarditis were attributed to bacterial infections: 2 patients 
had tuberculosis, 3 had purulent pericarditis (Staphylococ-
cus aureus, Serratia marcescens and Salmonella enterica) 
and 1 had syphilis. All patients were HIV negative. Other 
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pericarditis and pulmonary embolism were found in 5% of 
patients.
Patients with a known etiology (Table 2) were older (p = 
0.034), had more frequently pericardial effusion (p = 0.001), 
cardiac tamponade (p = 0.027) and presented with increased 
ESR values at admission (p = 0.002). Myopericarditis was 
more frequent among patients with idiopathic pericarditis (26 
out of 32 patients, p = 0.049). Among 9 patients with cardiac 
tamponade, only 3 had idiopathic pericarditis. The remaining 
6 patients had recognized etiology, notably post-myocardial 
injury (2), purulent pericarditis, tuberculosis, neoplasia, pulmo-
nary embolism and drug-induced pericarditis.
In the population studied, 71% of patients were treated 
with non-steroid anti-inflammatory drugs and 54% with colchi-
cine. Corticosteroids were used in 18% patients with refrac-
tory symptoms or systemic disease. There was no patient with 
idiopathic pericarditis receiving corticosteroid treatment (Table 
2). Additional treatment was implemented for specific etiol-
ogies, such as antibiotics for bacterial pericarditis (7%), hy-
droxycloroquine in the case of systemic lupus erythematosus 
(5%) and immunosuppression or chemotherapy (respectively 
4% and 2%). Combination of more than one pharmacologic 
treatment was frequent (52% of cases), with non-steroid anti-
inflammatory drugs and colchicine being the most frequent 
combination (43% of cases). Nine (10%) patients required 
pericardiocentesis for the management of pericardial effusion.
At 12-month follow-up after discharge, 13% of patients 
had at least one episode of recurrence of pericarditis, and it 
motivated hospitalization in 10% of all patients. The median 
time until the first pericarditis recurrence was 2 months (1-5). 
One patient developed constrictive pericarditis and underwent 
pericardial surgery. Neither specific etiology nor any of the clin-
ical parameters analysed were associated with a higher rate 
ETIOLOgIA, TRATAMENTO E PROgNóSTICO DA PERICARDITE AguDA




Age, years (IQR) 46 (32-61)
Male sex (%) 61 (65%)
Clinical features
Pericardial effusion (%) 54 (57%)
Myopericarditis (%) 32 (34%)
Cardiac tamponade (%) 9 (10%)
Etiology
Idiopathic 64 (68%)
Autoimmune disease 11 (12%)
Malignancy 5 (5%)













Pericarditis recurrence episodes 14
Patients with recurrence 12 (13%)
Hospitalization for recurrent pericarditis 9 (10%)
Median time in months until first 
recurrence (IQR)
2 (1-5)
Constrictive pericarditis 1 (1%)
Overall 1-year mortality 8 (9%)
NSAID - non-steroid anti-inflammatory drugs.
Tabela 2: Clinical features of patients with and without a 

























Myopericarditis 26 (41%) 6 (20%) 0.049
Pericardial effusion 29 (45%) 25 (83%) 0.001
Cardiac tamponade 3 (5%) 6 (20%) 0.027
Corticosteroid 
treatment




6 (9%) 6 (20%) 0,150
Overall 1-year 
mortality
0 8 (27%) < 0.001
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of recurrence. Of note, treatment with corticosteroids was not 
associated with pericarditis recurrence (p = 0.220).
The one-year overall mortality for acute pericarditis was 
9% (8 patients: 5 with malignancy, 2 with purulent pericardi-
tis, one with post-myocardial injury). Predictors of pericarditis 
1-year mortality at bivariate analysis are presented in Table 3. 
Multivariate model revealed that a defined etiology of pericar-
ditis was the only independent predictor of mortality (OR 40.3; 
95% CI 1.9 – 137.2; p = 0.016). Mortality was related with the 
underlying disease and not with pericarditis itself in a signifi-
cant proportion of patients (5 out 8 patients). The etiology of 
pericarditis among non-survivors was neoplasia in 5 patients, 
purulent pericarditis in 2 and post-myocardial injury in one. 
Cardiac tamponade was managed at in-hospital care and was 
not a direct cause of death in our cohort.
Discussion
In accordance with the literature,4-8 idiopathic pericarditis 
was the most prevalent etiology found in our study. About 
one-third of patients in our cohort had a specific systemic eti-
ology, which is slightly higher than previous reports.7 Like in 
our study, most studies state autoimmune disease and ma-
lignancy as the two most prevalent causes for acute pericar-
ditis.5-7 However, autoimmune disease was the etiology of 
pericarditis in a bigger proportion of patients (12%), than the 
average 3% - 7% reported in previous cohorts.7-12 Importantly, 
we found that acute pericarditis is the first manifestation of the 
disease in a considerable proportion of these patients. Post-
myocardial injury syndrome was present in 4% of patients, 
somewhat lower than the 20% reported on the population 
of colchicine randomized trials.11 Nevertheless, the recruit-
ment on these studies was based in cardiology and cardiac 
surgery departments, and some etiologies like tuberculosis 
were excluded from the trials, which may explain these dif-
ferences.11 The frequency of tuberculosis remains as low as 
2%, in accordance with the 1-3% reported in other Europe-
an studies. This is in contrast with the prevalence of pericar-
dial tuberculosis in African contrives, that represents about 
70% of all cases.7,8 Notably, purulent pericarditis was found 
in 3% of our population, somewhat higher than the < 1% re-
ported.7 Therefore, we believe it is important to look for the 
possibility of increasing incidence of purulent pericarditis dur-
ing the following years considering the increasing prevalence 
of immunocompromised patients, mainly due to cancer and 
inflammatory diseases treatments. Although most cases are 
idiopathic, our data emphasize the diversity of the etiology of 
acute pericarditis, with some uncommon cases reflecting a 
systemic underlying condition like uremic pericarditis or xan-
thogranulomatous pyelonephritis.14 Therefore, an integrated 
approach should always be attempted whenever a defined 
etiology is suspected.
We also found that patients with idiopathic pericarditis dif-
fered in some important clinical features from pericarditis with 
specific cause. While myopericarditis was more frequent in 
idiopathic pericarditis, a specific cause was associated with 
older age, elevated ESR, pericardial effusion and cardiac tam-
ponade. These results were similar to a prospective cohort 
from Imazio et al.13 Interestingly, tamponade was found almost 
only among patients with specific etiology (6 out of 9 patients). 
However, despite autoimmune disease being the most com-
mon specific etiology of pericarditis, no single patient with au-
toimmune disease developed cardiac tamponade.
The frequency of recurrence (13%) was low, when com-
pared with the literature (15% - 40%9). Previous studies on 
recurrence of pericarditis were performed before clinical tri-
als on colchicine, which is thought to halve the incidence 
of recurrences.10,11 Treatment with colchicine in a significant 
proportion of patients may explain the lower frequency in our 
population. No specific etiology was associated with the re-
currence rate. Likewise, no clinical feature (pericardial effu-
sion, myopericarditis, inflammatory markers) was found to be 
associated with an increased recurrence. So, mechanisms of 
recurrence may not be etiology associated and some data 
suggest that immune-mediated processes are involved in re-
current pericarditis, different from the mechanisms present in 
acute pericarditis.15 In our cohort, patients with a defined eti-
ology who were treated with corticosteroids were not found 
to have an increase in recurrences. This is in contrast with 
some previous reports9,14 in which they were used in patients 



























Defined etiology 22 (26%) 8 (100%) 0.008
Myopericarditis 31 (36%) 1 (13%) 0.209
Pericardial effusion 46 (53%) 8 (100%) 0.067
Cardiac tamponade 6 (7%) 3 (38%) 0.014
Corticosteroid 
treatment
13 (15%) 4 (50%) 0.025




11 (13%) 1 (13%) 0.981
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with idiopathic pericarditis at high doses. In our study, only 
patients with an identified cause were treated with cortico-
steroids (Table 2) at doses of 0.5-1.0 mg/kg. Therefore, our 
data suggest that at least in patients with a defined etiology, 
corticosteroid treatment is not associated with an increase in 
recurrence. Constrictive pericarditis occurred in very low num-
bers (one case of idiopathic pericarditis), not allowing making 
conclusions regarding this entity. This may reflect the low fre-
quency of tuberculosis pericarditis in our cohort, as constric-
tion is a recognizable complication among these patients.8
Besides the overall good prognosis, a known etiology of 
acute pericarditis was independently associated with an in-
creased risk of mortality. The fact that patients with a specific 
etiology have increased mortality strengthens the need to bet-
ter identify these patients. Increase in mortality in our study 
was mostly a result of malignancy and purulent pericarditis. 
Patients with cardiac tamponade also had significant mortality 
(3 out of 9 patients). However, tamponade did not reveal as a 
significant predictor of mortality on multivariate analysis. Most 
probably, this occurred because most cases of tamponade 
occurred in patients with specific causes (post-myocardial in-
jury or cancer). Moreover, tamponade was not a direct cause 
of death among these patients, most importantly underlying 
disease explained worse prognosis.
Mortality in patients with pericarditis was rarely addressed. 
Previous studies defined clinical predictors of pericarditis com-
plications (tamponade, recurrence, constriction),13,16 however 
mortality was not evaluated. Zayas et al6 also found an associa-
tion between specific etiology and unfavourable outcome. In a 
large Danish cohort, pericarditis patients were found to be at 
increased risk for cancer and patients with cancer and pericar-
ditis had higher mortality.17 On the other hand, purulent pericar-
ditis has also been associated with high mortality rates.18  
Several limitations of our study should be considered. 
Firstly, it is a retrospective study on hospitalized patients. In 
fact, there is few data concerning the etiology of acute peri-
carditis in ambulatory patients. Secondly, it reflects a single 
centre experience. Furthermore, there was no etiologic di-
agnostic protocol. However, a diagnostic protocol does not 
seem to offer a significant advantage over a physician decision 
diagnosis.7
Furthermore, the small sample used in this study is an-
other limitation to consider, particularly the small proportion 
of patients with defined etiology (30 patients). The outcome 
of interest on the prognostic analysis, 1-year after discharge 
overall mortality, was a relatively rare event (9% of patients). 
This may explain the wide and imprecise CI yielded by the 
multivariate logistic regression model for defined etiology as a 
predictor of mortality. Although this gives quite imprecise in-
formation regarding the risk of mortality for these patients, the 
results were quite significant and there were no deaths among 
patients with idiopathic pericarditis. That said, a defined etiol-
ogy has prognostic implication and mortality might be related 
more with underling disease than the pericarditis itself. Never-
theless, pericarditis is the first presentation of the disease in a 
significant proportion of patients with underling cause. In order 
to overcome the above limitations, larger multicentric stud-
ies are needed. Besides, the inclusion of ambulatory patients 
would also be of interest.
In conclusion, most cases of acute pericarditis were idio-
pathic, but up to one third of patients hospitalized for acute 
pericarditis had a known etiology. Autoimmune disease and 
malignancy were the most frequent etiologies found. Patients 
with a known cause of pericarditis had higher rates of tam-
ponade and an increased risk of mortality. Therefore, the iden-
tification of specific etiology for pericarditis has prognostic 
implications, which favours an integrated and individualized 
diagnostic approach to these patients.
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